NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Descending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50268-0154-13 | 50268-0154 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 12, 2018 | In Use | |
50268-0763-11 | 50268-0763 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 23, 2017 | July 31, 2021 | In Use |
50268-0763-12 | 50268-0763 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | March 23, 2017 | July 31, 2021 | In Use |
51808-0119-01 | 51808-0119 | I 131 Mini | I 131 Mini | 500.0 mCi/1 | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | May 23, 2012 | In Use | |
51862-0083-14 | 51862-0083 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | Sept. 30, 2019 | No Longer Used |
51862-0083-51 | 51862-0083 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | Sept. 30, 2019 | No Longer Used |
51862-0084-14 | 51862-0084 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
51862-0084-51 | 51862-0084 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
51862-0085-14 | 51862-0085 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | Sept. 30, 2019 | No Longer Used |
51862-0085-51 | 51862-0085 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | Sept. 30, 2019 | No Longer Used |
51862-0086-14 | 51862-0086 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
51862-0086-51 | 51862-0086 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | March 31, 2019 | In Use |
51862-0087-14 | 51862-0087 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | Sept. 30, 2019 | No Longer Used |
51862-0087-51 | 51862-0087 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | Sept. 30, 2019 | No Longer Used |
51862-0088-51 | 51862-0088 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct. 10, 2016 | Sept. 30, 2019 | No Longer Used |
53808-0411-01 | 53808-0411 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | July 1, 2009 | In Use | |
54482-0053-01 | 54482-0053 | Procarbazine Hydrochloride | Matulane | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Benzamide | Oral | Dec. 27, 1985 | March 31, 2020 | No Longer Used |
54868-4143-00 | 54868-4143 | Capecitabine | Xeloda | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Feb. 20, 2005 | In Use | |
54868-5667-00 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
54868-5667-01 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
54868-5667-02 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
54868-5667-03 | 54868-5667 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Sept. 8, 2006 | No Longer Used | |
55289-0924-30 | 55289-0924 | METHOTREXATE | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct. 23, 2009 | Aug. 3, 2018 | No Longer Used |
00093-8229-28 | 00093-8229 | Sunitinib Malate | Sunitinib Malate | 37.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec. 22, 2021 | In Use | |
00093-8231-28 | 00093-8231 | Sunitinib Malate | Sunitinib Malate | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec. 22, 2021 | In Use |
Found 10,000 results in 7 milliseconds — Export these results